CIBC World Market’s XORTX Therapeutics XRTX Stock Holding History

CIBC World Market’s Portfolio XRTX Stock Details XRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-47	Closed	-$16K	–	1360
2022 Q4	$16K	Hold	47	–	–	﹤0.01%	1226
2022 Q3	$23K	Sell	47 -20	-30%	-$11.3K	﹤0.01%	1211
2022 Q2	$36K	Buy	67 +11	+20%	+$6.96K	﹤0.01%	1233
2022 Q1	$44K	Hold	56	–	–	﹤0.01%	1277
2021 Q4	$46K	Buy	+56	New	+$57.6K	﹤0.01%	1298

Other funds holding XRTX

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CIBC World Market's XRTX Position: Q1 2023 in Review

CIBC World Market sold out of XORTX Therapeutics (XRTX) in Q1 2023, closing a stake of 47 shares — an estimated $16K sold.

CIBC World Market first reported a position in XRTX in Q4 2021 and held it in 5 quarters. The position peaked at $46K in Q4 2021. 5 funds tracked by Wall St. Rank hold XRTX as of Q1 2023.

CIBC World Market reported no remaining XORTX Therapeutics position as of Q1 2023 after selling out during the quarter.
CIBC World Market sold 47 XORTX Therapeutics shares in Q1 2023, an estimated $16K.
CIBC World Market first reported a position in XORTX Therapeutics in Q4 2021 and held it in 5 quarters.
CIBC World Market's XORTX Therapeutics position peaked at $46K in Q4 2021.
5 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q1 2023.

Based on CIBC World Market's 13F filing for Q1 2023, filed 12 May 2023.